American International Group Inc. raised its holdings in REGENXBIO Inc. (NASDAQ:RGNX) by 12.8% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,439 shares of the biotechnology company’s stock after buying an additional 2,888 shares during the period. American International Group Inc.’s holdings in REGENXBIO were worth $868,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its stake in REGENXBIO by 31.0% in the fourth quarter. JPMorgan Chase & Co. now owns 2,601,366 shares of the biotechnology company’s stock valued at $117,998,000 after buying an additional 615,254 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of REGENXBIO by 0.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 691,444 shares of the biotechnology company’s stock worth $31,366,000 after purchasing an additional 6,198 shares during the period. Korea Investment CORP increased its stake in shares of REGENXBIO by 9.9% during the fourth quarter. Korea Investment CORP now owns 489,971 shares of the biotechnology company’s stock worth $22,225,000 after purchasing an additional 44,300 shares during the period. Frazier Management LLC increased its stake in shares of REGENXBIO by 96.3% during the fourth quarter. Frazier Management LLC now owns 341,954 shares of the biotechnology company’s stock worth $15,511,000 after purchasing an additional 167,754 shares during the period. Finally, Norges Bank bought a new position in shares of REGENXBIO during the fourth quarter worth approximately $15,189,000. Hedge funds and other institutional investors own 76.51% of the company’s stock.
Shares of RGNX stock opened at $37.77 on Friday. The firm has a fifty day simple moving average of $35.01. The firm has a market cap of $1.61 billion, a P/E ratio of -12.11 and a beta of 1.22. REGENXBIO Inc. has a fifty-two week low of $25.92 and a fifty-two week high of $50.26.
RGNX has been the topic of a number of recent research reports. TheStreet lowered REGENXBIO from a “c” rating to a “d+” rating in a research note on Tuesday, February 16th. Morgan Stanley lowered their target price on REGENXBIO from $67.00 to $62.00 and set an “overweight” rating on the stock in a research note on Monday, March 8th. Finally, Zacks Investment Research upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Tuesday, May 11th. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $59.11.
REGENXBIO Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Featured Story: What can cause a stock to outperform?
Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNX).
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.